Skip to content
Open access

Enhancing Alzheimer’s disease diagnosis in primary care through targeted screening of people at risk of developing dementia – study design and feasibility assessment of the PREDEM primary care study

Sep 2026 · Alzheimer's Research & Therapy · Vol 18 · 0 citations · 58 references
Medicine

TL;DR

This pilot study demonstrates the feasibility of the PREDEM primary care study design and data collection procedures and targeted recruitment of older adults with cardiometabolic risk factors was able to identify a population relevant to the study aims.

Abstract

Timely detection of cognitive impairment due to Alzheimer’s disease (AD) is increasingly important as disease modifying therapies become available. Current diagnostic pathways in primary health care (PHC) rely mainly on clinical assessment and brief cognitive screening tools, which lack sensitivity for early impairment. Blood-based biomarkers (BBMs) show promising diagnostic potential in research settings. Targeted screening of individuals with cognitive symptoms and dementia risk factors using sensitive cognitive tests and reliable biomarkers may improve early AD detection in PHC. The PREDEM primary care study evaluates a targeted screening strategy combining a multidomain digital cognitive test battery and BBMs in individuals having elevated risk of dementia. This pilot study assessed the feasibility of recruitment, digital cognitive testing, biomarker sampling, and data collection. This descriptive pilot study was conducted at two PHC centres in Stockholm (April–October 2024). Eligible individuals were aged ≥ 65 years with hypertension or type 2 diabetes and self-reported memory complaints. Participants completed a screening question, followed by a demographic questionnaire, a multidomain digital cognitive test battery (Mindmore), MMSE, and blood sampling for four BBMs (GFAP, NF‑L, total tau, pTau217). Feasibility metrics included recruitment yield, test completion rates, participant characteristics, cognitive performance, and biomarker distributions. Of 548 identified individuals, 307 were invited and 40 were enrolled (13% participation). Among those enrolled, 37 completed all parts of the study. Digital home-based testing proved challenging: although 22 participants initially opted for home testing, only six completed it independently, and most required clinic-based support. Across cognitive tests, approximately one-third of participants scored below 1 standard deviation of normative performance, indicating detectable cognitive impairment. Non-native Swedish speakers (32%) showed significantly lower performance on verbally mediated tasks. Established cut-off values for pTau217 reflecting amyloid pathology showed pathological levels in 10–23% of participants depending on single or double cut-offs. This pilot study demonstrates the feasibility of the PREDEM primary care study design and data collection procedures. Targeted recruitment of older adults with cardiometabolic risk factors was able to identify a population relevant to the study aims. Key protocol refinements include removing the requirement for subjective memory complaints, conducting all cognitive testing at PHC, and optimization of cognitive test battery.

Read PDF

Similar papers

Review Open access Sep 2026

Diagnosis and management of mild cognitive impairment and mild Alzheimer's disease dementia: Findings from an Italian real-world survey

The real-world diagnostic journey, barriers, and management pathways of MCI and mild AD dementia patients in Italy is characterized to characterize the real-world diagnostic journey, barriers, and management pathways of biomarker-based diagnostics in Italy.

S. Ippati, Federico Torelli, Giovanna Zamboni et al. · 0 citations
Open access Sep 2026

Comparative Value of Cognitive and Functional Assessments for Predicting 24-Month Progression from Mild Cognitive Impairment to Alzheimer’s Disease: An ADNI Cohort Study

Episodic memory demonstrated the strongest predictive performance among the individual assessment domains evaluated of 24-month progression from MCI to AD, with functional assessment providing substantial complementary value.

Sophie Choe · 0 citations
Open access Sep 2026

Diagnostic accuracy of the ADAS-Cog-13 as a cognitive screening tool in older adults with focal epilepsy: A multicenter cross-sectional study.

The ADAS-Cog-13 may be a useful screening option in epilepsy research and clinical care, although additional studies are needed to compare it with other cognitive screening tests and to confirm its applicability for clinical care and across healthcare settings and cultures.

Jessica Kania, Ifrah Zawar, A. Reyes et al. · 0 citations
Review Open access Sep 2026

Clinical and attitudinal outcomes of a personalized, multimodal lifestyle intervention for Alzheimer's disease prevention in high-risk, cognitively normal older adults in north Alabama: A pilot study

INTRODUCTION: Multimodal lifestyle interventions can delay or slow Alzheimer's disease (AD) in at-risk older adults, and plasma pTau217, a blood-based biomarker, now enables scalable AD risk stratification. Population-level screening integrating genetic, biomarker, and lifestyle risk factors, alongside attitudes toward...

M. Cochran, J. Pugh, T. Coleman et al. · 0 citations
Open access Sep 2026

Dementia risk factors and biomarkers in subjective cognitive decline: real world evidence from the monza brain health service

Up to 45% of dementia can be prevented by addressing modifiable risk factors. Brain Health Services (BHS) are emerging across Europe, targeting individuals with subjective cognitive decline (SCD) to assess, communicate and reduce their risk of dementia. Our aim is to characterize our BHS cohort, and assess differences...

F. E. Pozzi, Francesca Solivani, I. Vitagliano et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.